Levin Capital Strategies, L.P. Ocular Therapeutix, Inc Transaction History

Levin Capital Strategies, L.P.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 31, 2023	SELL	$3.14 - $5.04 $31,400 - $50,400	-10,000 Reduced 30.77%	22,500 $70,000
Q2 2023 Jul 31, 2023	SELL	$4.6 - $7.64 $805,570 - $1.34 Million	-175,124 Reduced 84.35%	32,500 $167,000
Q1 2023 Apr 24, 2023	SELL	$2.79 - $6.27 $175,959 - $395,436	-63,068 Reduced 23.3%	207,624 $1.09 Million
Q4 2022 Feb 13, 2023	BUY	$2.61 - $4.41 $38,753 - $65,479	14,848 Added 5.8%	270,692 $760,000
Q3 2022 Nov 08, 2022	BUY	$4.09 - $6.5 $503,847 - $800,735	123,190 Added 92.87%	255,844 $1.06 Million

Q2 2022 Aug 15, 2022	BUY	$3.01 - $5.22 $399,288 - $692,453	132,654 New	132,654 $533,000
Q3 2020 Nov 17, 2020	SELL	$7.36 - $9.87 $542,270 - $727,201	-73,678 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$4.67 - $8.95 $203,976 - $390,918	43,678 Added 145.59%	73,678 $614,000
Q1 2020 May 13, 2020	SELL	$3.95 - $7.4 $59,250 - $111,000	-15,000 Reduced 33.33%	30,000 $148,000
Q4 2019 Feb 10, 2020	BUY	$2.57 - $4.73 $115,650 - $212,850	45,000 New	45,000 $178,000

148

123M

185K

507K

Ticker OCUL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,966,896
Market Cap $526M
Description
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cat...

Get notified when there are updates to the investment portfolio of Levin Capital Strategies, L.P., based on Form 13F filings with the SEC.

Stay updated on Levin Capital Strategies, L.P. with notifications on news.